Carolyn Mulroney
University of California, San Diego
Internal medicineCalcineurinOncologyPrecision medicineIntensive care medicineMultiple myelomaSerostatusChemotherapyCyclophosphamidePomalidomideDiseaseLymphomaMEDLINEGraft-versus-host diseaseSalvage therapyIxazomibDaratumumabStem cellCombined Modality TherapyTransplantationHodgkin lymphomaTransplant patientPhases of clinical researchIncidence (epidemiology)Clinical trialMedicineBiologyGastroenterology
34Publications
10H-index
311Citations
Publications 36
Newest
Abstract null Background null Methods that enable monitoring of therapeutic efficacy of autologous chimeric antigen receptor (CAR) T-cell therapy will be clinically useful. null Objectives null The aim of this study is to demonstrate the feasibility of blood-derived cell-free DNA (cfDNA) to predict CAR T-cell therapy response in patients with refractory B-cell lymphomas. null Study design null Whole blood was collected prior to and throughout CAR T-cell therapy until day +154. Low-coverage (∼0.4...
Source
#6Mohamed A. Kharfan-Dabaja (Mayo Clinic)H-Index: 19
ABSTRACT null null Background: There is increasing use of post-transplant cyclophosphamide (PTCy) for GVHD prophylaxis for both haploidentical and fully matched transplants. Published studies have reported an increased incidence of CMV infection with the use of PTCy. Limited data exist regarding the incidence and outcomes of infection with non-CMV herpes viruses (NCHV) in this setting. null Objective: The aim of this study was to evaluate the cumulative incidence of NCHV infections and the assoc...
Source
Community respiratory viral infections (CRVIs) are associated with pulmonary function impairment, alloimmune lung syndromes and inferior survival in human leucocyte antigen (HLA)-matched allogeneic haematopoietic stem cell transplant (HCT) recipients. Although the incidence of viral infections in HLA-haploidentical HCT recipients who receive post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis is reportedly increased, there are insufficient data describing t...
Source
#1Scott R. Goldsmith (WashU: Washington University in St. Louis)H-Index: 8
#2Muhammad Bilal Abid (MCW: Medical College of Wisconsin)H-Index: 11
Last. Christopher E. Dandoy (Cincinnati Children's Hospital Medical Center)H-Index: 29
view all 30 authors...
Prior studies suggest increased CMV infection following haploidentical donor transplantation with post-transplant cyclophosphamide (HaploCy). The role of allograft source and PTCy in CMV infection and disease is unclear. We analyzed the effect of graft source and PTCy on incidence of CMV infection as well as transplant outcomes as it relates to CMV serostatus and occurrence of CMV infection by d180. We examined patients reported to CIBMTR between 2012-2017 who had received HaploCy (n = 757), Sib...
Source
#1Huan You Wang (UCSD: University of California, San Diego)H-Index: 7
#2Ethan Sokol (Foundation Medicine)H-Index: 13
Last. Carolyn Mulroney (UCSD: University of California, San Diego)H-Index: 10
view all 5 authors...
The pathogenesis of follicular lymphoma is a multi-step process, in which chromosomal translocation between immunoglobulin heavy chain (IgH) and anti-apoptotic B-cell lymphoma 2 (BCL2), namely IgH-BCL2, is an earliest step, followed by other genetic/genomic alterations including but not limited to mutation of CREB binding protein (CREBBP). MHC class II transactivator (CIITA) is a transcription regulator responsible for expression of MHC class II molecules including HLA-DR in human. We report her...
Source
#1Lihua E. Budde (City of Hope National Medical Center)H-Index: 19
#2Michael Scordo (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 17
view all 13 authors...
Source
#1Michael Scordo (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 17
#2Lihua E. Budde (City of Hope National Medical Center)H-Index: 19
Last. Sergio Giralt (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 132
view all 12 authors...
Source
Source
#1Caitlin Costello (UCSD: University of California, San Diego)H-Index: 19
#2Benjamin Brookhart (UCSD: University of California, San Diego)
Last. Edward D. Ball (UCSD: University of California, San Diego)H-Index: 54
view all 6 authors...
Source
#1Richard T. Hoppe (Stanford University)H-Index: 111
#2Ranjana H. Advani (Stanford University)H-Index: 89
Last. Ndiya Ogba (National Comprehensive Cancer Network)H-Index: 15
view all 34 authors...
The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide recommendations for the management of adult patients with HL. The NCCN panel meets at least annually to review comments from reviewers within their institutions, examine relevant data, and reevaluate and update their recommendations. Current management of classic HL involves initial treatment with chemotherapy alone or combined modality therapy followed by restaging with PET/CT to assess treatment response. Overa...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.